View Older Stories View More Recent Stories
-
Merck receives $700 million from Blackstone for cancer drug development
-
Merck assumes full rights to MK-8690 drug after $150 million Falk deal
-
Merck (MRK) Tops Q3 EPS by 23c; narrows forecast
-
Stocks expected to have increasing option volume: MRK LLY GILD MA STLA HSY RDDT CI MSTR AMZN AAPL CMG WOLF
-
Merck (MRK) call put ratio 2.3 calls to 1 put into quarter results
-
European Commission approves Merck's KEYTRUDA for head and neck cancer treatment
-
Merck drug combination meets cancer trial endpoint in kidney cancer study
-
WELIREG plus LENVIMA meets key endpoint in kidney cancer trial
-
Merck to present phase 3 results for oral PCSK9 inhibitor at AHA meeting
-
Merck presents data on pneumococcal vaccine coverage at IDWeek
-
Merck KEYTRUDA shows long-term survival benefits in lung cancer patients
-
Merck begins construction of $3 billion manufacturing facility in Virginia
-
Citi Resumes Merck (MRK) at Neutral
-
Merck presents cancer research data at ESMO 2025 congress
-
Merck (MRK) there is no published scientific evidence that shows any benefit in separating the combination MMR vaccine into three individual shots
-
Merck starts phase 2b trials for tulisokibart in three new conditions
-
Merck (MRK) call put ratio 2.6 calls to 1 put with a focus on October 3 weekly calls
-
US Pausing Pharma Duties While Negotiations Ongoing - Politico
-
Trump on deal with Pfizer: we're going to be paying the lowest price, other drugmakers will commit in coming weeks
-
Trump says we’ll be reducing prices (of drugs) by a 100% and in some cases more
-
Bernstein on AmericasMedicines.com: 'The Noise Starts, But Not (Yet) from Trump'
-
EU will still have 15% pharma tariff, not 100% - Bloomberg
-
Verona Pharma shareholders approve $10 billion Merck acquisition
-
Merck enters $349M deal with Variational AI for drug discovery collaboration
-
FDA: approves pembrolizumab and berahyaluronidase alfa-pmph for subcutaneous injection
-
Merck receives positive EU opinion for RSV prevention drug ENFLONSIA
-
Merck receives positive EU opinions for KEYTRUDA subcutaneous form and head cancer use
-
Trump: tariffs will get countries to agree to drug pricing plan
-
Berenberg Downgrades Merck (MRK) to Hold
-
Daiichi Sankyo and Merck receive FDA breakthrough designation for ovarian cancer drug
-
Merck reports positive trial results for pneumonia vaccine in children
-
Raymond James Comments on FDA and HHS Reforms for DTC Pharma Advertising
-
Merck's oral cholesterol drug meets key goals in phase 3 trial
-
Merck to present cardiovascular disease research at ESC Congress
-
KEYTRUDA plus Padcev improves survival for bladder cancer patients
-
Trump Posts Letters to Regeneron, Merck, AstraZeneca, GSK, Pfizer, Novo Nordisk, Amgen, Bristol-Myears, AbbVie, Novartis, Gilead, J&J on Truth Social
-
Cantor Fitzgerald Reiterates Neutral Rating on Merck (MRK)
-
Merck (MRK) Tops Q2 EPS by 10c; narrows forecast
-
Merck (MRK) call put ratio 1 call to 1 put into quarter results
-
Merck (MRK) August 1 weekly 157.50 straddle into quarter results
-
Merck (MRK) Declares $0.81 Quarterly Dividend; 4% Yield
-
Merck commits to Veeva Vault CRM for commercial operations
-
Merck launches phase 3 trials for monthly HIV prevention pill
-
FDA approves Merck's BRAVECTO QUANTUM for year-long flea and tick protection
-
UBS Reiterates Buy Rating on Merck (MRK)
-
Morgan Stanley Reiterates Equalweight Rating on Merck (MRK)
-
Cantor Fitzgerald Reiterates Neutral Rating on Merck (MRK)
-
FDA accepts Merck's application for HIV two-drug regimen
-
Jefferies Downgrades Verona Pharma (VRNA) to Hold
-
Merck (MRK) eyes more M&A deals from $1b–$15b, open to exceeding range - CEO
